Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat.
- M. Marcus, K. Jardemark, M. Wadenberg, X. Langlois, P. Hertel, T. Svensson
- Biology, PsychologyThe international journal of…
- 1 September 2005
The combination of idazoxan and raclopride completely reversed the working-memory impairment in rats induced by MK-801, and define presynaptic alpha(2) adrenoceptors as major targets in antipsychotic drug development.
Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia
Its ability to increase both dopaminergic and glutamatergic activity in rat mPFC suggests that asenapine may possess an advantageous effect not only on positive symptoms in patients with schizophrenia, but also on negative and cognitive symptoms.
Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system
- J. L. Andersson, G. Nomikos, M. Marcus, P. Hertel, J. Mathé, T. Svensson
- Biology, PsychologyNaunyn-Schmiedeberg's Archives of Pharmacology
- 1 October 1995
Findings provide an experimental basis for the notion that combined 5-HT2 and D2 receptor antagonism may underlie the limbic mode of action of at least some atypical antipsychotic drugs and consequently contribute to their unique therapeutic effects.
Differential effects of acute and chronic nicotine on dopamine output in the core and shell of the rat nucleus accumbens
The results of the present experiments indicate that acutely administered nicotine or nicotine challenge in chronically pretreated animals with either saline or nicotine consistently increases DA release to a greater extent in the NACshell than in theNACcore, and that chronic nicotine pretreatment reduces the stimulatory action of nicotine on DA output in either the shell or the core subdivision of the Nac.
Effects of asenapine on prefrontal N‐methyl‐D‐aspartate receptor‐mediated transmission: Involvement of dopamine D1 receptors
The ability of asenapine to increase both cortical dopaminergic and NMDA receptor‐mediated glutamatergic transmission suggests that this drug may have an advantageous effect not only on positive symptoms in patients with schizophrenia, but also on negative and cognitive symptoms.
Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens
Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure.
Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms
- O. Frånberg, M. Marcus, V. Ivanov, B. Schilström, M. Shahid, T. Svensson
- Psychology, BiologyPsychopharmacology
- 7 February 2009
Asenapine at doses associated with antipsychotic activity enhanced cortical monoamine efflux and provided further insight on the pharmacologic characteristics of asenAPine that may have bearing on its clinical efficacy in the treatment of schizophrenia and bipolar disorder.
Effects of S‐citalopram, citalopram, and R‐citalopram on the firing patterns of dopamine neurons in the ventral tegmental area, N‐methyl‐D‐aspartate receptor‐mediated transmission in the medial…
The data suggest that the excitatory effect of escitalopram on dopaminergic and NMDA receptor‐mediated neurotransmission may have bearing on its cognitive‐enhancing effect and superior efficacy compared to other SSRIs in major depression.
Involvement of 5‐HT2A receptor and α2‐adrenoceptor blockade in the asenapine‐induced elevation of prefrontal cortical monoamine outflow
It is proposed that low concentrations of asenapine in the mPFC exhibit a pharmacologically significant 5‐HT2A and α2 receptor antagonistic activity, which may contribute to enhance prefrontal monoamine release in vivo and, secondarily, its clinical effects in schizophrenia and bipolar disorder.